Alfredo Miranda

TL;DR: The latest developments of the Open Targets Platform are presented, expanding the evidence and target-disease associations with new and improved data sources, refining data quality, enhancing website usability, and increasing the user base with training workshops, user support, social media and bioinformatics forum engagement.

TL;DR: To aid the prioritisation of targets and inform on the potential impact of modulating a given target, evaluation of post-marketing adverse drug reactions and new curated information on target tractability and safety are added.

TL;DR: Open Targets Genetics offers tools that enable users to prioritise causal variants and genes at disease-associated loci and access systematic cross-disease and disease-molecular trait colocalization analysis across 92 cell types and tissues including the eQTL Catalogue.

TL;DR: Open Targets Genetics as discussed by the authors is a community resource that provides systematic fine mapping at human GWAS loci, enabling users to prioritize genes at disease-associated regions and assess their potential as drug targets.

TL;DR: An open resource that provides systematic fine-mapping and protein-coding gene prioritization across 133,441 published human GWAS loci and trained a machine learning model to distinguish causal genes from background genes at the same loci, outperforming a naive distance based model.